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Abstract
We describe two studies encompassing the iterative 
refinement of a polymer-based rhBMP-2 delivery system 
for bone tissue engineering. Firstly, we compared the bone-
forming capacity of porous poly(D,L-lactic-co-glycolic 
acid) (PLGA) scaffolds produced by thermally induced 
phase separation (TIPS) with non-porous solvent cast 
poly(D,L-lactic acid) (PDLLA) used previously. Secondly, 
we examined the potential synergy between rhBMP-2 and 
local bisphosphonate in the PLGA scaffold system.
 In vivo ectopic bone formation studies were performed 
in C57BL6/J mice. Polymer scaffolds containing 0, 5, 10 or 
20 µg rhBMP-2 were inserted into the dorsal musculature. 
At all rhBMP-2 doses, porous PLGA produced significantly 
higher bone volume (BV, mm3) than the solid PDLLA 
scaffolds. Next, porous PLGA scaffolds containing 10 µg 
rhBMP-2 ± 0.2, or 2 µg zoledronic acid (ZA) were inserted 
into the hind-limb musculature. Co-delivery of local 10 µg 
rhBMP-2/2 µg ZA significantly augmented bone formation 
compared with rhBMP-2 alone (400 % BV increase, 
p < 0.01). Hydroxyapatite microparticle (HAp) addition 
(2 % w/w) to the 10 µg rhBMP-2/0.2 µg ZA group increased 
BV (200 %, p < 0.01). We propose that this was due to 
controlled ZA release of HAp-bound ZA. Consistent with 
this, elution analyses showed that HAp addition did not alter 
the rhBMP-2 elution, but delayed ZA release. Moreover, 
2 % w/w HAp addition reduced the scaffold’s compressive 
properties, but did not alter ease of surgical handling.
 In summary, our data show that refinement of the 
polymer selection and scaffold fabrication can enhance 
rhBMP-2 induced bone formation in our bone tissue 
engineering implant, and this can be further optimised by 
the local co-delivery of ZA/HAp.
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Introduction 
The Diamond Concept of bone tissue engineering 
proposes that a tissue engineering outcome is dependent 
on the selection of growth factors, type of scaffold 
or matrix, population(s) of osteogenic cells, and the 
amount of mechanical loading (Giannoudis et al., 2007). 
Recombinant human bone morphogenetic proteins 
(rhBMPs) such as rhBMP-2 and rhBMP-7/OP-1 can 
potently stimulate new bone formation and are clinically 
used in the treatment of spinal fusion, delayed and non-
unions, and critical sized bone defects. Purified collagen 
is the primary delivery system in clinical use. However, 
cost and prion-disease risk have led many groups to 
examine alternative delivery systems. As previously 
reviewed by our group, biodegradable polymers are 
emerging as promising synthetic biomaterials for the 
controlled release of osteogenic growth factors (Yu et al., 
2010a). Furthermore, synthetic materials avoid potential 
immunogenic response or disease transfer associated with 
collagen materials (DeLustro et al., 1990; Geesink et al., 
1999; Olsen et al., 2003; Kato et al., 2006).
 Bone resorption can be particularly problematic in 
situations where rhBMPs are used. High BMP local 
concentrations can increase osteoclast activity (Kaneko 
et al., 2000; Itoh et al., 2001) and cause premature bone 
resorption (Pradhan et al., 2006). In addition, many tissue-
engineering implants are unloaded or subjected to stress 
shielding, which can also increase resorptive pressures 
(Wolff, 1892). In a model described by us in 2005, we 
proposed that optimal orthopaedic repair requires an 
appropriate balance between anabolism (bone formation) 
and catabolism (bone resorption) (Little et al., 2005; Little 
et al., 2007). In the context of bone tissue engineering the 
use of anti-resorptive agents may compensate for bone 
loss due to poor mechanics and potentially maximise bone 
outcomes (Yu et al., 2012 ).
 A number of preclinical studies have shown synergy 
between rhBMPs and bisphosphonates. Systemic 
bisphosphonate dosing given immediately post-operatively 
or 2 weeks post-operatively increased rhBMP-7/OP-1 
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induced bone formation in a rat critical-sized defect model 
(Little et al., 2005). This led to increased union rates 
and mechanical strength at 6 weeks. Other studies have 
illustrated advantages of this systemic bisphosphonates 
dosing in a rat ectopic bone formation model (Gong et 
al., 2003), an unloaded rat bone chamber model (Tägil et 
al., 2006; Harding et al., 2008), and non-human primate 
models (Bouxsein et al., 2001; Seeherman et al., 2001).
 For bisphosphonates, local delivery has emerged as an 
appealing alternative to systemic delivery for two reasons. 
Firstly, local dosing can lower the absolute bisphosphonate 
dose required. Secondly, systemic bisphosphonates 
are associated with adverse events including stomach 
ulceration (oral bisphosphonates) and flu-like symptoms 
(intravenous dosing) (Thiébaud et al., 1997; Mönkkönen et 
al., 1998), and in rare cases renal failure and osteonecrosis 
of the jaw (Marx, 2005). A number of studies have 
shown positive effects by delivering both rhBMPs and 
bisphosphonates locally (Jeppsson et al., 2003; Chen et 
al., 2004; Chen et al., 2006; Belfrage et al., 2011).
 Our group has previously examined the effects of 
combining rhBMP-7 with local bisphosphonate (0.02 mg, 
0.2 mg, and 2 mg pamidronate) in solvent cast poly(D,L-
lactic acid) (PDLLA) discs (Yu et al., 2010b). After 3 
weeks, local low dose pamidronate (0.02 mg) was found 
to augment rhBMP-2 induced bone formation to a similar 
capacity to systemic co-treatment (0.3 and 3.0 mg/kg, thrice 
weekly). Notably, local high dose pamidronate (2 mg) 
adversely affected bone formation, highlighting potential 
negative effects that have been previously associated 
with high local concentrations of bisphosphonate (Choi 
et al., 2007; Jakobsen et al., 2007; Jakobsen et al., 2010). 
Consequently, we further speculated that the addition 
of a calcium phosphate based biomaterial, which could 
sequester and/or delay local bisphosphonate release, may 
further improve bone formation outcomes. In addition, 
bound bisphosphonate may be preferentially phagocytosed 
by osteoclasts (Coathup et al., 2001).
 This report details a systematic process for developing 
an alternative synthetic biodegradable delivery system for 
rhBMP-2 delivery. This involved a two-step process for 
validating the biomaterial selection and fabrication process 
using a range of rhBMP-2 doses, and for the introduction 
of zoledronic acid (ZA) and hydroxyapatite microparticles 
(HAp). The thermally induced phase separation (TIPS) 
manufactured PLGA polymer was selected based on its 
faster degradation rate, as PDLLA discs showed poor 
biodegradation in a prior study with 3 and 8 week endpoints 
(Yu et al., 2010b). This study shows, for the first time, the 
potential of rhBMP-2 delivery by a TIPS manufactured 
scaffold, which combines modulation by locally delivered 
anti-resorptive drugs.
Materials and Methods
Experimental design
In the first animal study, porous PLGA scaffolds and 
solvent cast PDLLA discs were compared as rhBMP-2 
delivery systems in a mouse dorsal muscle pouch model. 
A range of rhBMP-2 doses were examined (Table 1). In 
the second animal study, the dose of 10 µg rhBMP-2 in 
porous PLGA scaffolds was selected for further refinement. 
Scaffolds were tested with and without 0.2 µg ZA, 2 µg 
ZA, and 0.2 µg ZA with 2 % w/w HAp microparticles in 
a hind-limb muscle pouch model. A systemic ZA dosing 
group was also included (Table 1). For all in vivo models, 
the end point was 3 weeks.
 To investigate the PGLA scaffolds mechanistically, 
scanning electron microscopy, compression testing, and 
Table 1. Surgical experimental groups.
Group Surgical model Polymer scaffold Local anabolic agent Anti-catabolic agent Animals Exclusions
1 Dorsal muscle pouch Solid PDLLA
rhBMP-2
(0, 5, 10, 20 µg) 0 µg ZA 6*
0 (0 µg rhBMP-2)
0 (5 µg rhBMP-2)
1 (10 µg rhBMP-2)
0 (20 µg rhBMP-2)
2 Dorsal muscle pouch
Porous PLGA
(quick quench, TIPS)
rhBMP-2
(0, 5, 10, 20 µg) 0 µg ZA 6*
0 (0 µg rhBMP-2)
1 (5 µg rhBMP-2)
0 (10 µg rhBMP-2)
0 (20 µg rhBMP-2)
3 Dorsal muscle pouch
Porous PLGA
(slow quench, TIPS)
rhBMP-2
(0, 5, 10, 20 µg) 0 µg ZA 6*
0 (0 µg rhBMP-2)
0 (5 µg rhBMP-2)
1 (10 µg rhBMP-2)
0 (20 µg rhBMP-2)
4 Hind-limb muscle pouch
Porous PLGA
(slow quench, TIPS)
10 µg rhBMP-2 0 µg ZA 8 0
5 Hind-limb muscle pouch
Porous PLGA
(slow quench, TIPS)
10 µg rhBMP-2 Local 0.2 µg ZA 8 0
6 Hind-limb muscle pouch
Porous PLGA
(slow quench, TIPS)
10 µg rhBMP-2 Local 2 µg ZA 8 2
7 Hind-limb muscle pouch
HAp/Porous PLGA
(slow quench, TIPS)
10 µg rhBMP-2 Local 0.2 µg ZA(via 2 % HAp) 8 1
8
Hind-limb muscle 
pouch
Porous PLGA
(slow quench, TIPS)
10 µg rhBMP-2 Systemic 0.1 mg/kg(2 µg ZA total) 8 2
* Each animal was implanted with same scaffold type with 4 different rhBMP-2 doses.
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elution studies were conducted to characterise the scaffold 
architecture, mechanical properties, and drug release 
kinetics respectively. A range of HAp concentrations, 
including the 2 % w/w used in in vivo experiments, were 
tested by compression (Table 2). Drug elution studies took 
place over 3 weeks, with rhBMP-2 being measured by 
enzyme-linked immunosorbent assay (ELISA) (Table 3) 
and 14C-radiolabelled ZA by scintillation counting (Table 
4).
Reagents
Recombinant human Bone Morphogenetic Protein-2 
(rhBMP-2) from INFUSE® Bone Graft Small Kit was 
purchased from Medronic (Memphis, TN, USA) and 
Zoledronic Acid (ZA) was purchased from AXXORA (San 
Diego, CA, USA). For in vitro studies, a stock solution of 
14C radiolabelled ZA (14C-ZA) with a specific activity of 
7.027 MBq/mg was supplied by Novartis Pharma (Basel, 
Switzerland).
 Poly-D,L-lactic-acid (PDLLA) biodegradable polymer 
(inherent viscosity 0.55-0.75 dl/g, average MW 75,000-
120,000; Sigma-Aldrich, Sydney, Australia) and organic 
solvent, ethyl acetate (analytic reagent grade, Chem Supply, 
Port Adelaide, Australia) were used for the fabrication of 
the solid PDLLA discs. Poly(D,L-lactide-co-glycolide) 
(PLGA) biodegradable polymer (lactide:glycolide ratio 
of 50:50 and inherent viscosity 0.95-1.20 dl/g, Durect, 
Lactel©, Pelham, AL, USA) and solvent 1,4-dioxane 
(99 % ACS reagent, Gliwice, Poland) were used for the 
fabrication of porous PLGA scaffolds. Collagen from 
INFUSE® Bone Graft Small Kit (Medronic, Memphis, 
TN, USA) was used as supplied.
 Precalcined hydroxyapatite (HAp) microparticles 
with an average diameter ~1.5 µm were used (P149, 
Plasma Biotal, Buxton, Derbyshire, UK). Particles were 
agglomerates of acicular nanoparticles (diameter ~100 nm 
x 250 nm) (Ruys et al., 1995). ZA was adsorbed to HAp 
following protocol previously published by Seshima et 
al. (Seshima et al., 2006) and Shi et al. (Shi et al., 2009). 
Briefly, ZA/sterile water solution (1 mg/mL) was incubated 
with HAp (37 ºC water bath for 24 h), filtered, and the 
remaining ZA-HAp vacuum-dried (for 8 h at -70 kPa and 
45 ºC).
Production of solvent-cast PDLLA discs
Solid solvent-cast PDLLA discs containing 10 μg rhBMP-2 
were manufactured as previously described (Yu et al., 
2010b). In brief, rhBMP-2 and PDLLA/ethyl acetate 
solutions were mixed by vortex and sonication. The solvent 
was vacuum evaporated and the remaining rhBMP-2/
Table 2. Mechanical testing polymer scaffold groups.
Group Polymer scaffold Hap % w/w (of PLGA) n
1 Porous PLGA
(slow quench, SQ TIPS)
0 % 5
2 HAp/Porous PLGA
(slow quench, SQ TIPS)
1 % 7
3 HAp/Porous PLGA
(slow quench, SQ TIPS)
2 % 7
4 HAp/Porous PLGA
(slow quench, SQ TIPS)
5 % 6
5 HAp/Porous PLGA
(slow quench, SQ TIPS)
10 % 5
6 HAp/Porous PLGA
(slow quench, SQ TIPS)
25 % 5
Table 3. In vitro rhBMP-2 elution scaffold groups.
Group Scaffold Local anabolic agent Local anti-catabolic agent n
1 Collagen 10 µg rhBMP-2 - 3
2 Porous PLGA
(slow quench, SQ TIPS) 10 µg rhBMP-2 - 3
3 HAp/Porous PLGA
(slow quench, SQ TIPS)
10 µg rhBMP-2 - 3
4 Porous PLGA
(slow quench, SQ TIPS)
10 µg rhBMP-2 0.2 µg ZA 3
5 HAp/Porous PLGA
(slow quench, SQ TIPS)
10 µg rhBMP-2 0.2 µg ZA (via 2 % HAp ) 3
6 Porous PLGA
(slow quench, SQ TIPS)
10 µg rhBMP-2 2 µg ZA 3
Table 4. In vitro radiolabelled ZA elution scaffold groups.
Grp Polymer scaffold Local anabolic agent Local anti-catabolic agent n
1 Porous PLGA
(slow quench, SQ TIPS)
10 µg rhBMP-2 - 3
2 Porous PLGA
(slow quench, SQ TIPS)
10 µg rhBMP-2 0.2 µg 14C-ZA 3
3 HAp/Porous PLGA
(slow quench, SQ TIPS)
10 µg rhBMP-2 0.2 µg 14C-ZA (via 2 % HAp) 3
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PDLLA was compressed into disks (3 mm diameter and 
1 mm height) and UV-sterilised for 2 min.
Production of porous PLGA scaffolds by thermally 
induced phase separation
Porous PLGA scaffolds containing 10 μg rhBMP-2 ± ZA 
± HAp were produced by a modified thermally induced 
phase separation (TIPS) method from Cao et al. (Cao et 
al., 2004; Cao et al., 2006a; Cao et al., 2006b) and Jack 
et al. (Jack et al., 2009). In brief, a PLGA/dioxane stock 
solution was diluted with dioxane-containing drug ± HAp 
solutions to give a final concentration of 10 % w/v. The 
polymer + drug/dioxane solutions were mixed by vortex 
and sonication. Composite HAp/PLGA scaffolds were 
loaded with HAp at 2 % w/w. The final solutions were 
transferred into glass moulds and quenched in a -18 ºC 
freezer (quick quench, QQ) or underwent controlled 
cooling from 25 ºC to -10 ºC at a rate of -0.5 ºC/min (slow 
quench, SQ). Once removed from glass moulds, quenched 
scaffold rods were placed under low vacuum (8 h, 7.3 x 
10-5 KPa) for solvent removal. Vacuum-dried scaffold rods 
were sliced into discs (3 mm diameter and 1 mm height) 
with a stainless steel blade (N35, Feather Safety Razor, 
Osaka, Japan). The disks were UV sterilised for 2 min.
Scanning electron microscopy
Surfaces of all porous PLGA scaffolds groups (including 
those with HAp) were visualised with scanning electron 
microscopy (SEM). Two scaffolds were used per scaffold 
group. Samples were cut with a stainless steel blade to 
produce transaxial and sagittal surfaces. Samples were 
adhered to standard SEM stubs and sputter-coated with 
gold/palladium (11 nm). Secondary electron images 
were captured with Philips XL 30 CP microscopy system 
(Philips, Sydney, Australia) at 15 kV.
Compression testing of PLGA ± HAp scaffolds
The mechanical effect of HAp addition to PLGA at 
various percentage weight compositions (0, 1, 2, 5, 10 
and 25 % w/w) was determined by compressive testing 
of porous PLGA TIPS (slow quenched) scaffolds. 
Cylindrical scaffolds (10 mm diameter x 5 mm height) 
were compressed with an Instron Mechanical Tester 5944 
with a 100 N load cell (Instron, Norwood, MA, USA). All 
tests were performed at 0.10 min-1 strain rate (i.e., cross 
head rate of 0.5 mm/min). An average of n = 5 per scaffold 
group was tested (Table 2). Compressive strength (MPa) 
and compressive modulus (MPa) were collected with 
BlueHill 3 software.
Animal care and surgery
Female C57BL6/J mice were purchased from the Animal 
Resources Centre (Perth, WA, Australia) and used at 8-10 
weeks (average weight 18 g) for all in vivo studies. Animals 
were allowed 1 week acclimatisation to local vivarium 
conditions prior to surgery. Animal studies were approved 
by the local animal ethics committee (AEC, K294/10) and 
animals were given chow and water ad libitum.
 Surgical introduction of scaffolds/discs was performed 
based on a previously published methodology (Yu et al., 
2010b). Anaesthesia was induced with an intraperitoneal 
injection of 35 mg/kg ketamine and 4.5 mg/kg xylazine 
and maintained with inhaled isoflurane. In a modification 
of the published model, for the first study 4 implants were 
introduced to the dorsal musculature of mice containing 
doses of 0, 5, 10 and 20 µg rhBMP-2 (Table 1). For the 
second study, a single implant was introduced to the hind 
limb, as per our standard model (Yu et al., 2010b). Each 
scaffold contained 10 µg rhBMP-2 ± 0.2, or 2 µg zoledronic 
acid (ZA) ± 2% w/w HAp (Table 1). Following surgery, 
animals were allowed to recover and monitored post-
operatively and given saline and buprenorphine (0.05 mg/
kg) to manage dehydration and post-operative pain and 
monitored by weekly weighing. A subset of animals dosed 
with 0.1 mg/kg ZA by subcutaneous injection (s.c.) if 
systemic dosing was indicated. This ZA dose is considered 
comparable to that used for clinical management of 
osteoporosis dose on a milligram per kilogram basis, 
and has been used previously by our group (Smith et al., 
2004; Little et al., 2005). Animals were euthanised by CO2 
asphyxiation at 3 weeks after surgery.
Radiographic imaging and micro-computed 
tomography (microCT)
Ectopic bone nodule placement relative to surrounding 
bone structure was assessed in two-dimensions by digital 
X-ray (Faxitron X-ray Corp, Wheeling, IL, USA) at 
27 kV and 2× magnification). Samples were excluded 
from analysis if the ectopic bone nodule had fused with 
an adjacent bone structure (e.g., vertebrae or femur), or if 
the scaffold was found to have shifted out of the muscle 
pouch subsequent to surgery.
 Three-dimensional (3D) measurement and analysis 
was carried out by microCT. Samples were scanned in 
70 % ethanol with SkyScan 1174 compact μCT scanner 
(SkyScan, Kontich, Belgium) at 11.97 μm pixel resolution 
and with 0.5 mm aluminium filter, 50 kV X-ray tube 
voltage, 800 μA tube electric current, and 4500 ms scanning 
exposure time. MicroCT images were reconstructed using 
NRecon (version 1.6.1.7, SkyScan) and three dimensional 
assessments were conducted with CTAnalyser software 
(version 1.10.9.0, SkyScan). The primary outcome 
measurement was bone volume (BV, mm3). Secondary 
outcome measurements for the hind-limb muscle pouch 
studies included bone tissue mineral density and pellet 
nodule volume. Bone tissue mineral density (bone TMD, 
mg/cm3 of hydroxyapatite) was as defined by Bouxsein 
et al. (Bouxsein et al., 2010) as the material density of 
bone tissue region only. The bone tissue was defined as 
calcified tissue detected by microCT using predetermined 
thresholds as shown in Fig. 1A. The pellet nodule volume 
(PNV, mm3) was defined as the total volume occupied by 
the nodule, including the outer cortical shell and inner bone 
and pseudo marrow cavity. This is visually represented in 
Fig. 1B.
 Representative three-dimensional bone nodule 
reconstructions were generated from ectopic bone 
samples with BV closest to the group’s mean. Samples 
were reconstructed with transaxial slices (0.42 mm) from 
the pellet nodule’s mid-section with CTVol Realistic 
Visualisation software (version 2.1.0.0, SkyScan).
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Histological analysis of bone formation
Samples were harvested post-mortem, fixed in 4 % 
paraformaldehyde, and stored in 70 % ethanol for 
radiographic and histological analysis. Samples were 
decalcified at 4 °C on a shaker in 0.34 M EDTA (pH 8.0) 
containing 0.5 % paraformaldehyde for 3 days, followed by 
27 days in 0.34 M EDTA changed every 3 days. Decalcified 
samples were processed to paraffin. Transaxially halved 
samples were embedded in paraffin. 0.5 mm-thick sections 
were cut using a Leica RM 2155 Microtome (Leica 
Microsystems, Wetzlar, Germany). Sections were stained 
with alcian blue and picrosirius red for cartilage and bone. 
Stained sections were scanned with ScanScope digital 
slide scanner (Aperio Technologies, Vista, CA, USA), 
and images were captured with ImageScope (Aperio 
Technologies). Observational histology was conducted 
on all samples from the hind-limb muscle pouch studies.
In vitro rhBMP-2 and 14C-ZA elution analysis
Release of rhBMP-2 and radiolabelled 14C-ZA from porous 
PLGA TIPS (slow quenched) scaffolds (3 mm diameter 
and 1 mm height) was measured over 3 weeks as per Table 
3 and Table 4; n = 3 scaffolds were measured per group. 
Samples were incubated at 37 °C in Protein LoBind tubes 
(Eppendorf, Stevenage, UK) containing 2 mL of elution 
buffer (1 % bovine serum albumin/phosphate buffered 
saline, BSA/PBS) formulated to prevent adsorption to the 
vessel. At time points of 1 h, 1 day (24 h), 1 week (168 h), 
and 3 weeks (504 h), scaffolds were transferred to new 
tubes containing fresh elution buffer. Collected samples 
were stored at -20 °C.
 The amount of rhBMP-2 drug released was quantified 
using a Quantikine® BMP-2 Immunoassay (PDBP200, 
R&D Systems, Wiesbaden, Germany) as per the 
manufacturer’s instructions. 14C-ZA was measured with 
Tri-Carb scintillation counter (Packard, MN, USA) 
using scintillation cocktail (5 mL Ultima Gold DIPN, 
PerkinElmer, Waltham, MA USA) and counted in 20 mL 
Pico Prias polyethylene vials (Perkin-Elmer). Remaining 
14C-ZA was measured by solubilising the residual scaffold 
with 2 mL ethyl acetate. Values were compared to a 
standard curve generated from 14C-ZA standards.
Statistical analyses
Statistical analyses of in vitro drug elution data was 
conducted with one-way ANOVA with Dunnett’s post-hoc 
test. Statistical significance was set at α < 0.05. Analysis 
for mechanical testing was conducted with non-parametric 
tests (Kruskal Wallis and Mann Whitney U). For analyses 
of microCT data from animal studies, non-parametric 
statistical tests (Kruskal Wallis and Mann Whitney U) 
were carried out, as these complex biological models 
could not be assumed to follow a normal distribution. All 
tests were performed using SPSS Statistics version 17 
(SPSS, Chicago, IL, USA). Statistical significance was 
set at α < 0.05.
Results
SEM analysis of porous PGLA scaffolds generated by 
TIPS
The surface morphology of TIPS-fabricated scaffolds was 
characterised by scanning electron microscopy (SEM) to 
reveal a highly porous structure with interconnected pores. 
Slow quench (SQ) TIPS scaffolds showed an isotropic 
pore structure while quick quench (QQ) TIPS scaffolds 
demonstrated an anisotropic (aligned) pore structure, with 
round and tubular-shaped pores directed to the centre of the 
scaffold. Pore structure was not affected by the presence or 
absence of rhBMP-2 or HAp microparticles (Fig. 2). The 
scaffold porosity was 90 %. The pore size diameter range 
of SQ scaffold loaded with 10 µg rhBMP-2 ± ZA (0.2 µg 
and 2 µg) ± 2 % w/w HAp was 20-200 µm (average pore 
diameter 70 µm).
Compression testing of PLGA ± HAp scaffolds
The effect of HAp addition on the mechanical properties 
of porous PLGA scaffolds was examined by compression 
Fig. 1. Two-dimensional slices of microCT images 
representing (A) the bone tissue region versus (B) the 
pellet nodule region. Scale bar = 2 mm.
Fig. 2. Representative SEM images of the porous TIPS PLGA scaffold architecture. Examples of quick-quenched 
(QQ) scaffolds, slow-quenched (SQ) scaffolds, and SQ scaffolds with hydroxyapatite microparticles (HAp) are 
shown. Arrowheads highlight the channels interconnecting adjacent pores. Scale bar = 50 µm.
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testing. Various HAp percentage weight compositions 
(0, 1, 2, 5, 10 and 25 % w/w) were tested. Compared to 
porous PLGA alone scaffolds, the addition of 1 % and 
2 % HAp reduced compressive strength (37 % and 55 % 
respectively, p < 0.05). A 54 % reduction in compressive 
modulus (p < 0.01) was found with 2 % w/w HAp addition. 
In contrast, no change in compressive properties was found 
with higher percentage weight compositions at 5, 10 or 
25 % w/w (Fig. 3).
Comparison of porous PLGA scaffolds versus solid 
PDLLA discs
To compare the porous PGLA scaffolds versus the solid 
PDLLA discs used previously by us (Yu et al., 2010b), 
delivery of a range of rhBMP-2 doses were assessed in 
an in vivo ectopic bone formation assay. No bone nodules 
formed in the absence of rhBMP-2. BV was found to be 
significantly higher for the PGLA TIPS scaffolds groups 
for all rhBMP-2 doses (160-270 % increase, p < 0.05) (Fig. 
4). The bone induced by 5 µg rhBMP-2/porous PLGA (QQ/
SQ) TIPS scaffold was comparable to 20 µg rhBMP-2/
solid PDLLA discs (N.S. p = 0.89). Sub-group analysis of 
SQ versus QQ scaffolds of the 10 µg and 20 µg rhBMP-2 
groups showed no significant difference in BV between 
the two quenching methods.
 3D microCT reconstructions of ectopic bone nodules 
illustrated differences between the two scaffold/pellet 
designs (Fig. 5). All delivery systems featured a cortical 
Fig. 3. Compressive properties of porous PLGA scaffolds ± HAp (0, 1, 2, 5, 10 and 25 % w/w). (A) Compressive 
strength and (B) compressive modulus. Error bars represent standard deviation and *p < 0.05 vs. PLGA scaffold alone.
Fig. 4. Bone volume (BV, mm3) of ectopic bone nodules at 3 weeks post-scaffold insertion. *p < 0.05 vs. solid 
PDLLA disc of same rhBMP-2 dose. Error bars represent standard deviation. n = number of samples remaining 
following exclusions.
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outer shell, but the PGLA TIPS pellets showed significantly 
more internal trabeculae than the solid PDLLA discs. 
Additionally, the PDLLA group had poor biodegradation 
and the centre of these specimens contained significant 
residual polymer. These observations were further 
confirmed on histological sections with alcian blue and 
picrosirius red staining (Fig. 6).
Local co-delivery of rhBMP-2 and bisphosphonate 
via porous PLGA scaffolds
The capacity of local bisphosphonate delivery to enhance 
rhBMP-2 induced bone was further refined based on using 
10 µg rhBMP-2 in the PGLA (SQ TIPS) scaffolds. In the 
hind-limb model, net bone at 3 weeks was significantly 
increased with local co-delivery of 2 µg ZA (400 % 
increase in BV vs. rhBMP-2 alone, p < 0.01). Systemic 
ZA (0.1 mg/kg) co-treatment also resulted in increased 
bone (610 % increase in BV versus rhBMP-2 alone, 
p < 0.01), and this was comparable to 2 µg local ZA (N.S, 
p = 0.34). The lower dose of 0.2 µg ZA did not alter net 
bone formation (7 % BV decrease, N.S) (Fig. 7).
 Pellet nodule volume (PNV, mm3), which reflects the 
overall nodule size, was significantly higher with 2 µg 
local ZA (110 % increase, p < 0.01), but not with 0.1 mg/
kg systemic ZA (45 % increase, N.S) (Fig. 8). These ZA 
dosing regimens also led to significant increases in bone 
tissue mineral density (bone TMD) compared to rhBMP-2 
alone nodules (9 % increase, p = 0.01 and 23 % increase, 
p < 0.01 for local and systemic respectively) (Fig. 9). 
Representative microCT 3D reconstructions were used to 
visualise these findings and images representing the median 
BV for each group are shown (Fig. 10).
 Observational histology of bone regions confirmed that 
there was considerable retention of the primary spongiosa 
in the in the 2 µg local ZA group and 0.1 mg/kg systemic 
ZA group (data not shown).
Co-delivery of rhBMP-2 and ZA-adsorbed HAp 
microparticles
An additional group included in the hind-limb model 
was scaffolds containing 10 µg rhBMP-2 + 0.2 µg ZA 
+ 2 % w/w HAp where the ZA was pre-adsorbed to the 
hydroxyapatite. It was hypothesised that this may prevent 
or ameliorate the burst release of ZA from the scaffolds and 
thus lead to improved biological outcomes. While 0.2 µg 
ZA was not sufficient to BV compared to controls, the dose 
pre-adsorbed onto HAp led to significant increases in BV 
compared to rhBMP-2 alone (174 % increase, p < 0.01) 
Fig .  5 .  Represen ta t ive 
microCT 3D reconstructions 
of rhBMP-2 induced bone 
nodules resulting from solid 
PDLLA scaffolds and porous 
PLGA quick quench (QQ)/
slow quench (SQ) scaffolds. 
Scale bar = 5 mm.
Fig. 6. Histological images 
of alcian blue and picrosirius-
stained sections. (A) solid 
PDLLA disc, (B) porous PLGA 
QQ scaffold, and (C) porous 
PLGA SQ scaffold. Higher 
magnifications are shown in 
A’, B’, and C’ respectively. 
Scale bar = 500 µm. PDLLA 
r e s i d u e  a r e  b o u n d  b y 
arrowheads.
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and local 0.2 µg ZA (195 % increase, p < 0.01) (Fig. 7). 
The pellet nodule volume (PNV, mm3) of local 0.2 µg 
ZA ± HAp was comparable to rhBMP-2 alone (Fig. 8). 
Comparable increases were seen in bone TMD compared 
to rhBMP-2 alone (13 %, p < 0.01) and local 0.2 µg 
ZA (11 %, p = 0.02) (Fig. 9). MicroCT reconstructions 
revealed that co-treatment of rhBMP-2 and HAp-ZA led 
to increased bone sheath thickness and increased bone 
in-growth (Fig. 10).
Elution of rhBMP-2 and ZA from porous PLGA 
scaffolds
The rhBMP-2 release of PLGA scaffolds was modelled in 
vitro over 3 weeks and quantified by ELISA. In all groups 
there was a burst release within the first hour (55-65 % 
of the total rhBMP-2 released), which was followed by a 
sustained drug release (Fig. 11A). The inclusion of HAp 
did not affect the rhBMP-2 release. Nevertheless, the total 
release of rhBMP-2 represented less than 2 % of the total 
rhBMP-2 incorporated into the scaffold, although the 
scaffolds did not undergo any biodegradation comparable 
to that seen after surgical implantation. Porous collagen 
scaffold used in clinical delivery was used as a control, and 
the amount of rhBMP-2 released from collagen scaffold 
was significantly higher than PLGA TIPS scaffold at all 
time-points (390 % at 1 h and average of 170 % from 
24-504 h, p < 0.01), but again less than 10 % of the total 
rhBMP-2 originally added was detected by ELISA.
 To test the in vitro release of radiolabelled 14C-ZA 
and examine the effects of HAp inclusion, eluents were 
measured by scintillation counting. A group lacking 14C-ZA 
was included to determine background. In PLGA scaffolds 
containing 10 μg BMP + 0.2 µg 14C-ZA, 51 % of the total 
ZA eluted was released from the BMP + ZA scaffold 
group in the first hour. In samples containing HAp, this 
was reduced to 29 % in the first hour (Fig. 11B). By 24 h 
the groups without and with HAp had released 88 % and 
55 % respectively. No difference was seen at the 3 week 
time point with all of the 14C-ZA detected as having been 
eluted from the PGLA scaffolds. The total ZA released at 3 
weeks and ZA loaded per scaffold were consistent between 
the groups.
Fig. 7. Bone volume (BV, mm3) of ectopic bone nodules 
at 3 weeks post-scaffold insertion. *p ≤ 0.01 vs. BMP 
controls and +p < 0.01 vs. BMP + 0.2 µg ZA. n = number 
of samples analysed after exclusions.
Fig. 8. Pellet nodule volume (PNV, mm3) of ectopic bone 
nodules at 3 weeks post-scaffold insertion. *p < 0.01 vs. 
BMP controls and #p < 0.03 vs. BMP + systemic ZA.
Fig. 9. Bone tissue mineral density (TMD, mg/cm3) of 
ectopic bone nodules at 3 weeks post-scaffold insertion. 
*p ≤ 0.01 vs. BMP control, #p < 0.01 vs. BMP + systemic 
ZA, and +p < 0.05 vs. BMP + 0.2 µg ZA.
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Discussion
Based on the fundamental concepts of maximising bone 
anabolism while minimising bone catabolism, this study 
describes the iterative refinement of a polymer-based 
scaffold for bone tissue engineering. We have previously 
published on the application of a solid solvent-cast 
PDLLA polymer disc for the co-delivery of rhBMP-7 and 
pamidronate (Yu et al., 2010b). However, this material 
showed poor biodegradation that was speculated to yield 
suboptimal drug release as well as potentially interfere 
with new bone formation in the interior of implants. 
Consequently, we have developed a new porous PLGA 
polymer delivery system for the delivery of rhBMP-2. As 
adjunctive agents, we have explored that addition of the 3rd 
generation bisphosphonate ZA to reduce bone resorption, 
and HAp microparticles. HAp microparticles were tested 
to facilitate the controlled release of ZA. HAp also has 
osteoconductive and anti-inflammatory potential, and thus 
may have positive effects on bone formation independent 
of ZA binding (Athanasiou et al., 1996; Calandrelli et al., 
2000; Rizzi et al., 2001; Calandrelli et al., 2004; Kim et 
al., 2004; Jung et al., 2005; Causa et al., 2006; Rezwan 
et al., 2006; Yu et al., 2009). However, including a series 
of HAp only controls was outside the scope of this study.
 This scaffold approach focuses on local co-delivery of 
BMP and bisphosphonate. Current clinical applications and 
prior tissue engineering work typically features systemic 
delivery of bisphosphonates, however the ability to avoid 
adverse effects associated with systemic dosing make local 
dosing an appealing alternative. Our prior study using 
solid PDLLA discs demonstrates proof of principle that 
local bisphosphonate lead to yield superior outcomes (Yu 
et al., 2010b), although there is an underlying potential 
for overdosing. Other groups have also shown effects with 
local high dose bisphosphonate (via PLGA scaffold or bone 
graft) on calvarial defect healing (Choi et al., 2007) or 
implant fixation (Jakobsen et al., 2007). The importance of 
appropriate local dosing has been further corroborated by 
a recent study showing that lower doses of bisphosphonate 
zoledronic acid could increase in bone-implant fixation 
while higher doses were inhibitory (Jakobsen et al., 2010). 
The mechanism behind adverse local effects is unclear, but 
could be due to toxicity (Idris et al., 2008). While it may be 
speculated that adsorption to HAp may reduce local toxic 
effects, we have not yet specifically addressed this in our 
model system.
 Our previous work showed synergy between 
rhBMP-7 and local bisphosphonate (Yu et al., 2010b); 
however, we speculated that porous PLGA would yield 
superior outcomes. PLGA possesses faster degradation 
characteristics and an extensive FDA approval history. To 
further increase polymer degradation rate, porous PLGA 
scaffolds were fabricated by thermally phase separation 
technique (TIPS). TIPS is a solvent-based method that 
allows tailored interconnected pores of desired size and 
distribution (Cao et al., 2004; Cao et al., 2006a; Cao et al., 
2006b) and our protocol was modified from the seminal 
paper of Cao et al. (Cao et al., 2004; Cao et al., 2006a; 
Cao et al., 2006b). The resultant scaffold achieved a 90-
95 % porous PLGA matrix with highly ordered cellular 
pore structures and high interconnectivity. Porosity and 
interconnectivity are important for cell migration, oxygen, 
nutrient and metabolite supply to cells, waste transfer, and 
tissue ingrowth (Guillemin et al., 1989; Mikos et al., 1994; 
Mooney et al., 1994; Liu and Ma, 2004; Hollister, 2005). 
Furthermore, the faster biodegradation rate of 50:50 PLGA 
compared with PDLLA (Middleton and Tipton, 2000) may 
affect drug release, although this could not be modelled 
using in vitro elution studies.
Fig. 10. Representative 
microCT 3D reconstructions 
of ectopic bone nodules 
from rhBMP-2 controls, 
and co-treated with local 
ZA ± HAp or systemic ZA. 
Scale bar = 5 mm.
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Fig. 11. In vitro drug elution characteristics 
over 3 weeks: (A) rhBMP-2 elution 
from porous PLGA ± HAp scaffolds and 
collagen scaffolds. (B) 14C-ZA elution 
from porous PLGA scaffolds ± HAp. Error 
bars represent standard error mean.
 Comparison of bone formation for porous PLGA 
scaffolds versus solid PDLLA scaffolds showed PLGA 
producing more bone at all rhBMP-2 doses. The increase 
was 3 to 4-fold, representing a major increase in implant 
efficiency. PLGA scaffolds also showed increased bone 
in-growth. Samples from the 5 µg rhBMP-2 SQ and QQ 
PLGA groups were unintentionally combined as one group 
(quick/slow quench TIPS) prior to implantation; although 
other rhBMP-2 doses showed no significant differences 
between SQ and QQ. Porous PLGA slow quench TIPS 
scaffolds were selected for the next phase of testing due 
to the capacity for future manipulation of pore structure 
by controlling the cooling rate.
 Next, anabolic and anti-catabolic synergy was explored 
using ZA doses that were predicted to be below the threshold 
for adverse effects on bone formation. A consistent 10 µg 
rhBMP-2 dose was used to induce ectopic bone formation. 
The 2 µg local ZA dose significantly increased BMP-
induced bone formation and bone mineral density with 
comparable bone volume to 0.1 mg/kg systemic ZA (i.e., 
total dose of 2 µg ZA). Thus, local delivery could approach 
the efficacy of systemic delivery without the potential 
risks associated with systemic dosing. These data were 
consistent with previous studies showing enhancement of 
BMP-induced bone formation with bisphosphonate co-
delivery (Jeppsson et al., 2003; Chen et al., 2004; Chen 
et al., 2006; Jakobsen et al., 2007; Jakobsen et al., 2010; 
Yu et al., 2010b; Belfrage et al., 2011). This is likely due 
to bisphosphonate binding or becoming incorporated into 
the newly formed and unloaded bone and preventing its 
resorption. We have previously shown that local dosing 
with pamidronate can reduce TRAP+ cells in a rhBMP-7 
induced bone formation model (Yu et al., 2010b). A similar 
study using local rhBMP and systemic bisphosphonate, 
incandronate also showed reduced osteoclast number 
(Gong et al., 2003).
 Finally, we explored the addition of HAp microparticles 
for pre-adsorption of ZA and incorporation into the 
polymer scaffold. Since bisphosphonates have an affinity 
for calcium phosphate, in both synthetic HAp and natural 
HAp in bone (Coathup et al., 2001), it was hypothesised 
that ZA-bound HAp could delay release or even be 
preferentially phagocytosed by osteoclasts (Coathup et 
al., 2001). Consistent with this concept, pre-adsorption of 
0.2 µg ZA onto 2 % w/w HAp led to a significant 2.7-fold 
increase in bone volume at 3 weeks compared to rhBMP-2 
alone and rhBMP-2 + 0.2 µg ZA.
 Studies have shown bisphosphonate release from 
HAp to be at a controlled rate (Seshima et al., 2006) and 
indeed, we saw a trend towards slower release of 14C-
ZA from porous PLGA scaffolds in our in vitro studies. 
Interestingly, the elution of 14C-ZA was largely complete 
by 3 weeks, with all groups showing ~100 % elution and 
no radioactivity could be detected in the residual pellet. 
In contrast, rhBMP-2 elution was significantly less in 
all groups, including collagen scaffold controls. One 
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explanation for this discrepancy could be the relative sizes 
of the molecules, although it is possible that rhBMP-2 
could degrade in vitro so that total activity detected was 
significantly less than the original rhBMP-2 added.
 The addition of 1 % w/w HAp to porous PLGA reduced 
the scaffold’s compressive strength (37 %, p < 0.05), while 
2 % w/w HAp addition led to reductions in compressive 
strength and compressive modulus (54 % and 55 % 
respectively, p < 0.01). In contrast, Jack et al. (Jack et 
al., 2009) reported a 3-fold increase in compressive 
modulus with 2 % w/w nano-sized HAp addition to porous 
polymeric scaffolds, although the HAp size, polymer 
type, and quenching regime differed to our study. In this 
study, it was surmised that the decrease in compressive 
properties found in the 1-2 % w/w HAp groups was due to 
the insufficient bonding between HAp within the polymer 
matrix. Dispersion of HAp particles may attribute to this; 
however, uniform HAp distribution was ensured during 
the polymer fabrication. Furthermore, a precursor study by 
Jack et al. demonstrated uniform HAp dispersion within 
the polymer matrix (Jack et al., 2009). In a previous study, 
it was found that lower HAp contents of < 30 % w/w did 
not significantly increase compressive properties (Wei and 
Ma, 2004). It should be noted that during surgical handling, 
we observed no difference in scaffold structural integrity 
between porous PLGA scaffolds ± 2 % w/w HAp.
 This study has several intrinsic limitations due to the 
simplicity of the in vivo model. While it allowed for rapid 
screening at low costs for the number of independent 
samples tested, the resultant bone nodules were small 
and irregular and poorly suitable outcomes such as 
mechanical testing. Future studies looking at non-union 
or critical defect healing would be more suitable for 
examining mechanical parameters. They would also be 
able to evaluate an implant’s applicability for bone repair 
as opposed to new ectopic bone formation. Nevertheless, 
these data have demonstrated in principle the efficacy 
of co-delivering rhBMP-2, low dose ZA, and HAp via a 
porous PLGA polymer scaffold in a pre-clinical model. 
These data represent a significant advancement in polymer 
based implant design for bone tissue engineering.
Conclusion
We have previously reported that low doses of local 
bisphosphonates can augment bone formation in a 
tissue-engineering model. In this study, we describe 
the development and testing of porous PLGAs loaded 
with a combination of rhBMP-2 and ZA-adsorbed HAp 
microparticles led to a maximal bone formation response. 
These studies demonstrate how scaffold design, anabolic 
and anti-catabolic drug doses, and the interactions between 
the two can be sequentially optimised to produce a highly 
effective implant. Future up-scaled experiments in more 
sophisticated orthopaedic models will be required to 
facilitate the clinical translation of this multifactorial 
approach.
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Discussion with Reviewers
J. Gasser: Ideally, mechanical properties of the PLGA and 
PDLLA discs should be assessed. Please also discuss how 
the differences in material, porosity, degradation rate and 
other factors could have influenced the results.
Authors: Additional control groups examining BMP 
+ HAp (without ZA) were not tested for several reasons. 
Firstly, post-hoc addition of extra groups would not 
have been scientifically valid, as the gold standard for 
orthopaedic studies is to perform all surgeries at the same 
time under identical conditions. Secondly, these were not 
part of our original hypothesis that HAp could bind and 
enhance the effects of ZA; understanding the capacity 
of HAp to affect bone in the absence of ZA is a separate 
research question that we believe merits its own focused 
study.
Reviewer II: Do you think that addition of a bisphosphonate 
could lower the required BMP dose in current clinical 
settings, and thereby reduce the important adverse effects 
of BMP-2, which were recently highlighted by Carragee 
et al. (2011) (additional reference).
Authors: Our data would suggest that this is the case, 
although to date the majority of preclinical studies (such 
as those cited in the introduction and discussion) have 
concentrated on using equivalent rhBMP doses and 
showing increases in bone with bisphosphonates. Notably, 
using an optimised delivery system can yield equal bone 
volume for a lesser rhBMP-2 dose (5 µg rhBMP-2 in 
porous PLGA = 20 µg rhBMP-2 in solvent cast PDLLA). 
However, we recognise a need to be conservative when 
drawing conclusions from preclinical models and further 
testing is required to validate this in a clinical setting. Still, a 
capacity to use reduced rhBMP-2 doses by bisphosphonate 
addition while avoiding potential adverse events gives 
further justification for pursuing this line of research.
Reviewer II: Heterotopic bone formation is a regularly 
seen negative side-effect of the use of supraphysiological 
concentrations of BMP-2 in clinical situation. Based on 
the results of this study, would you expect addition of 
bisphosphonates to the implants containing BMP-2 to 
affect incidence of heterotopic bone formation around the 
defect area and if so, in which way?
Authors: The addition of bisphosphonates to the implants 
containing BMP-2 is not expected to affect the incidence of 
heterotopic bone formation around the defect area. Based 
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on this heterotopic bone formation study, local release of 
BMP-2 + bisphosphonate (via hydroxyapatite ceramic 
particles at 2 % w/w) did not result in a significant increase 
in ectopic bone formation, compared to BMP-2 alone. 
The representative 3-dimensional microCT representative 
images showed bone in-growth into the scaffold instead of 
bone formation spreading away from the scaffold space.
Reviewer III: You suggest that future studies should be 
performed in large animals in models of critical defect 
healing. Could you please comment on the exact model 
to be used, and what your expectations are regarding 
the outcome, taking into account differences in species, 
orthotopic environment, loading, etc.?
Authors: Our current future plans involve a two stage 
process of preclinical testing. Based on positive results 
in an ectopic bone formation model (described in this 
paper), we next plan to test the implant design in an 
established rat critical-sized defect model (Little et al., 
2005, text reference). This model features a 6 mm critical-
sized full-thickness with periosteal stripping and internal 
plated fixation. We expect that ZA/HAp co-treatment will 
perform better than BMP alone. This model will be a better 
reflection of the type of orthopaedic injury that the implant 
is designed to treat.
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protein-2 trials in spinal surgery: emerging safety concerns 
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